Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L.
P/B ratio for Recordati Industria Chimica e Farmaceutica S.p.A. (REC.MI)
P/B ratio as of 2023: 5.97
According to Recordati Industria Chimica e Farmaceutica S.p.A.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.97. At the end of 2022 the company had a P/B ratio of 5.15.
P/B ratio history for Recordati Industria Chimica e Farmaceutica S.p.A. from 2003 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 5.97 |
| 2022 | 5.15 |
| 2021 | 8.42 |
| 2020 | 7.31 |
| 2019 | 6.42 |
| 2018 | 6.37 |
| 2017 | 7.52 |
| 2016 | 6.14 |
| 2015 | 5.68 |
| 2014 | 3.32 |
| 2013 | 3.00 |
| 2012 | 2.10 |
| 2011 | 1.87 |
| 2010 | 2.43 |
| 2009 | 2.02 |
| 2008 | 1.71 |
| 2007 | 3.18 |
| 2006 | 3.15 |
| 2005 | 3.56 |
| 2004 | 3.34 |
| 2003 | 2.96 |